About
MabGenesis develops therapeutic monoclonal antibody drugs for humans and companion animals using proprietary antibody libraries and isolation technologies, targeting diseases such as cancer and zoonotic diseases in humans and various diseases in dogs and cats.
Explore MabGenesis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.